Invex Therapeutics

🚨Over the past few months, Invex Therapeutics was on the brink of something extraordinary - a potential acquisition that could have positioned us at the forefront of rare neurological disease innovation, specifically in Fragile X Syndrome, a US$1.4 billion global market with no approved therapies. Our Board had advanced negotiations with a company nominated for a major global award, one we believed represented a genuine, value-creating opportunity for all shareholders. Unfortunately, those discussions came to a halt following the disruption caused by a Section 249D requisition, brought forward by an investor whose motives and direction for Invex and their long term interests of all shareholders is currently unknown. Indeed, Invex is in the complete dark about the Requisitioning Shareholder's strategy and direction for Invex as he has been conspicuously silent on its plans including any proposed directors. This intervention has not only destabilised a near-final transaction, but also delayed our ability to deliver on our diversification strategy, a strategy designed to unlock long-term value and bring much-needed therapies to patients who currently have none. As Directors, we are deeply disappointed, not for ourselves, but for what has been lost: a credible path to growth, a stronger future for our shareholders, and hope for patients in the rare neurological disease community. We remain steadfast in our focus and commitment to rebuilding that opportunity through integrity, science, and strategy, not self-interest. For more, read our market update here: https://lnkd.in/gKZjSdbW #ASX #IXC #Invex

Invex Therapeutics is attending the 19th Bioshares Biotech Summit in Hobart this week! We’re joining Australia’s leading biotech and investor forum to connect with industry leaders, share insights, and explore new opportunities. With over 35 life sciences companies presenting, it’s a great chance to engage with the innovation shaping our sector. Looking forward to a productive two days in Hobart! #Bioshares #Biotech #ASX #InvexTherapeutics #LifeSciences #InvestorRelations #IXC Invex Therapeutics Thomas Duthy

This week Invex Therapeutics released our Quarterly report to the ASX for the June Quarter. Our mission is to unlock our full potential of Exenatide in treating neurological conditions tied to raised intracranial pressure. Key highlights from the report include; 🧠 Smarter trial design: We're revamping inclusion criteria and endpoints to streamline recruitment, without compromising on scientific rigor. 📉 Resource efficiency: The protocol redesign will reduce sample size from 240 to 130 patients, keeping the overall budget intact 💰 Solid financials: With ~A$5.4million (as of 30 June 2025), we're well-positioned to execute our plans As we recalibrate, we're more nimble than ever and remain committed to adding value for patients and shareholders alike. 📑 Click here to view the full report: https://lnkd.in/gbr-6T5H #ASX #Ausbiotech #biotech #invex $IXC

That’s a wrap on Day 3 #BIO2025! Another productive day of meetings, insights, and invaluable connections. The global interest in treatments for neurological conditions continues to grow — and we’re proud to be part of the conversation. A big thank you to everyone who said hi, shared ideas, and opened the door to future collaboration. One more day to go! hashtag #InvexTherapeutics #BIOInternational #Neuroscience #Biotech hashtag #Pharma #Partnering #HealthcareInnovation #IXC 📸: Highlights from Day 3 feat. Invex Executive Director Thomas Duthy and Chairman David McAuliffe on the ground in Boston Biotechnology Innovation Organization

Day 3 kicked off with a bang in Boston! #BIO2025 Biotechnology Innovation Organization

Great to have our Directors, Thomas Duthy and David McAuliffe representing Invex on the ground at #BIO2025 in Boston this week. They’re here meeting with potential partners, investors, and peers — and always open to new conversations around innovation and cutting edge technology. 📍If you see them around the conference, don’t hesitate to say hello! #BIOInternational #InvexTherapeutics #Biotech #Neuroscience #Partnering #InvestorRelations #invex #IXC Biotechnology Innovation Organization

Day 1 at #BIO2025 has been non-stop — and we wouldn’t have it any other way. From insightful discussions to back-to-back meetings with global leaders in biotech and pharma, we’re energised by the momentum. Exciting exhibits today from companies like Pfizer, Samsung Biologics, Simcere Pharmaceutical Group, and more — all focused on innovation and partnership. Looking forward to Day 2! 📍Boston | #InvexTherapeutics #BIOInternational #BIOBoston #NeuroendocrineDisorders #Biotech #Pharma #Partnerships #IXC #GlobalHealth

⚕️Invex Therapeutics are proud to be attending the world’s premier biotechnology conference in Boston this week with a packed line up of meetings with investors, partners, and global life sciences leaders underway. 📍Attending #BIO2025? Get in touch, we'd love to connect. Biotechnology Innovation Organization #BIO2025 #BIOBoston#BIOInternationalConvention #Biotech #BrainHealth #Neuroscience #LifeSciences #HealthcareInnovation #BostonBiotech #Invex #IXC $IXC

Invex Therapeutics is thrilled to be joining over 20,000 of the worlds leading innovators in Boston this week for the world's largest bio tech conference. #BIO2025 is in full swing and we can't wait! 🧬⚙️🩸🔬⚕️ #BIO2025 #biotech #Invex #IXC $IXC Biotechnology Innovation Organization #Boston